Scancell’s Melanoma Trial Achieves Success, Paving the Way for Phase III

Scancell Holdings PLC’s latest update brings promising results from its phase II SCOPE melanoma study featuring its lead ImmunoBody therapy, iSCIB1+. CEO Phillip L’Huillier revealed the trial met its primary goals, giving the company clear guidance on dosing, patient populations, and design for an upcoming registrational phase III clinical trial, expected to start in late 2026. The newly released data showed a 74% progression‑free survival rate at 16 months for patients treated with iSCIB1+, compared with 46% at 12 months for the current standard‑of‑care treatment involving dual checkpoint inhibitors Ipilimumab and Nivolumab — a result described as a “strong and durable benefit.” Scancell also reported meaningful clinical benefit across patient subgroups where existing therapies often underperform, including those with BRAF mutations, varying PD‑L1 status, and prior checkpoint treatment exposure. The positive data has clarified the company’s development strategy, strengthening its position for future regulatory feedback, financing, and partnership discussions as it advances toward late‑stage clinical development. #Scancell #MelanomaTrial #ImmunoBody #ClinicalResearch #SlimScan #GrowthStocks #CANSLIM